Cargando…
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463270/ https://www.ncbi.nlm.nih.gov/pubmed/34589395 http://dx.doi.org/10.1016/j.apsb.2020.12.020 |
_version_ | 1784572366025654272 |
---|---|
author | Tang, Guoyi Li, Sha Zhang, Cheng Chen, Haiyong Wang, Ning Feng, Yibin |
author_facet | Tang, Guoyi Li, Sha Zhang, Cheng Chen, Haiyong Wang, Ning Feng, Yibin |
author_sort | Tang, Guoyi |
collection | PubMed |
description | Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN. |
format | Online Article Text |
id | pubmed-8463270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-84632702021-09-28 Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management Tang, Guoyi Li, Sha Zhang, Cheng Chen, Haiyong Wang, Ning Feng, Yibin Acta Pharm Sin B Review Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN. Elsevier 2021-09 2021-02-02 /pmc/articles/PMC8463270/ /pubmed/34589395 http://dx.doi.org/10.1016/j.apsb.2020.12.020 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Tang, Guoyi Li, Sha Zhang, Cheng Chen, Haiyong Wang, Ning Feng, Yibin Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title_full | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title_fullStr | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title_full_unstemmed | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title_short | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
title_sort | clinical efficacies, underlying mechanisms and molecular targets of chinese medicines for diabetic nephropathy treatment and management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463270/ https://www.ncbi.nlm.nih.gov/pubmed/34589395 http://dx.doi.org/10.1016/j.apsb.2020.12.020 |
work_keys_str_mv | AT tangguoyi clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement AT lisha clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement AT zhangcheng clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement AT chenhaiyong clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement AT wangning clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement AT fengyibin clinicalefficaciesunderlyingmechanismsandmoleculartargetsofchinesemedicinesfordiabeticnephropathytreatmentandmanagement |